-
Signature
-
/s/ Jonathan Young, Attorney-in-Fact
-
Issuer symbol
-
AKRO
-
Transactions as of
-
10 Oct 2025
-
Net transactions value
-
-$1,023,240
-
Form type
-
4
-
Filing time
-
14 Oct 2025, 20:11:47 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Cheng Andrew |
President and CEO, Director |
C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO |
/s/ Jonathan Young, Attorney-in-Fact |
14 Oct 2025 |
0001778307 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
AKRO |
Common Stock |
Options Exercise |
$596,100 |
+30,000 |
+5.7% |
$19.87 |
556,114 |
10 Oct 2025 |
Direct |
F1 |
| transaction |
AKRO |
Common Stock |
Sale |
$1,619,340 |
-30,000 |
-5.4% |
$53.98 |
526,114 |
10 Oct 2025 |
Direct |
F1, F2 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
AKRO |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-30,000 |
-7.3% |
$0.000000 |
380,017 |
10 Oct 2025 |
Common Stock |
30,000 |
$19.87 |
Direct |
F1, F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: